Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06424912
Other study ID # CIP-001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 30, 2024
Est. completion date June 30, 2026

Study information

Verified date May 2024
Source Vivifi Medical
Contact Yiming Deng
Phone 4083966040
Email yideng@rqmplus.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study objective is to evaluate the safety and feasibility of the Vivifi's Treatment. The Vivifi's Treatment presents an innovative approach for addressing benign prostatic hyperplasia (BPH) as well as clinical/subclinical varicoceles in men. The scientific rationale for conducting this study is to assess the safety and feasibility of the Vivifi's Treatment (a surgical procedure) as a therapeutic intervention for patients with BPH.


Description:

Current BPH treatments fall into two major categories: 1. Surgical removal/destruction of prostatic tissues: 1. Transurethral resection of the prostate (TURP) 2. Holmium laser enucleation of the prostate (HoLEP) 3. Aquablation - (Procept) 4. Prostatic artery embolization (PAE) 2. Minimally-invasive Surgical Therapies (MISTs) 1. Itind (now Olymus) 2. Urolift (now Teleflex) 3. Rezum (now Boston Scientific) 4. TUNA 5. Zenflow (in trials) 6. Butterfly Medical (in trials) The solutions in the first category rely in removing or destroying prostatic tissue. Though effective at reducing urinary symptoms, this damage to the tissue can cause a number of complications. The "non-surgical" solutions fall into the second category. One of the best-studied of these, Urolift, is an implant-based therapy, using internal sutures that are deployed though the urethra that pull the prostatic tissue away from the urethra lumen, repristinating urethral patency. A significant percentage of cases show recurrence of symptoms due to the fact that the prostate continues to grow. Looking at the currently available treatment options, the longer-lasting surgical procedure (group 1). Group 1 procedures, especially TURP, remain "the gold standard" by which all other BPH treatment options are measured. The Vivifi's Treatment aims to fill the therapeutic gap between the two-category approaches by offering patients a less invasive surgical approach that (1) fixes the root cause of the problem, guaranteeing long lasting effects and (2) does not cause any damage to the prostatic tissue and urethra, thereby preventing the side effects mentioned above. By replumbing a faulty localized vasculature, the Vivifi's technology leverage years of safety data for anastomotic coupling rings enabling it for vascular surgical approaches. These initial clinical studies will prove that this totally novel treatment approach to BPH is safe.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date June 30, 2026
Est. primary completion date January 30, 2026
Accepts healthy volunteers No
Gender Male
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: 1. Male 40-75 years of age 2. Diagnosed with Benign prostatic hyperplasia (BPH) 3. Prostate volume: = 30 = 120 cc measured by transrectal ultrasound 4. Signed the study informed consent form (ICF) 5. Presence of Lower Urinary Tract Symptoms (LUTS) measured by International Prostate Symptoms Score (IPSS) greater than 12 6. Presence of clinical varicocele (preferably grade II or III - Dubin & Amelar. Exclusion Criteria: 1. Patients with prior history of spermatic vein or pampiniform plexus related surgeries or impairment, or vasectomy 2. Previous invasive prostate intervention (TURP, laser, ablation, prostate artery embolization, etc.) 3. Prostate with large intravesical median lobe 4. Patients with sub-clinical varicocele 5. Post-void residual volume (PVR) > 110ml 6. IPSS (International Prostate Symptoms Score) >24 7. Patients with clinical history of chronic prostatitis. 8. Patients with clinical history of urinary retention with previous need for catheterization (prior 30 days). 9. Major neurological conditions such as Alzheimer's, Parkinson, Multiple sclerosis, ALS, spinal cord injury 10. Patients that can not be under general anesthesia 11. Patients on blood thinners, or with coagulation related issues, TTP 12. Prior pelvic floor surgery or condition such as inguinal hernia, mesh, etc 13. History of cancer in genitourinary system, which is not considered being cured. A potential participant is considered cured if there has been no evidence of cancer within five years of the study. 14. Inability to provide legally effective Informed Consent Form (ICF) and/or comply with all of the required follow-up requirements 15. Subject currently participating in other investigational studies unless approved by the Sponsor in writing

Study Design


Intervention

Procedure:
Vivifi's Surgical Procedure
Subjects undergo Vivifi's surgical procedure for treatment of BPH. The study procedure will be performed in the operating room, under general anesthesia. Subject will undergo a bilateral anastomosis of the internal spermatic vein to the inferior epigastric vein and ligation of the deferential vein via bilateral inguinal/subinguinal incision. The investigators can use of a coupler with appropriate ring size (to be measured intra-operatively based on vessel size) to perform the vascular anastomosis and standard sutures for ligation. The coupler is an FDA approved commercial device. Alternatively, the anastomosis can also be performed using sutures. Incision closure will proceed per institution standard of care.

Locations

Country Name City State
Panama National Hospital Panama City Punta Pacifica

Sponsors (2)

Lead Sponsor Collaborator
Vivifi Medical RQMplus

Country where clinical trial is conducted

Panama, 

Outcome

Type Measure Description Time frame Safety issue
Primary PRIMARY SAFETY ENDPOINT Assess the safety of the Vivifi's Treatment through the rate & type of the procedure related complications, such as bleeding, infection or other tissue damage. will be assessed up to 12-month post-procedure follow-up.
Primary PRIMARY EFFICACY ENDPOINT Assess the changes in International Prostate Symptoms Score (IPSS) from baseline to post-procedure. The score range of the questionnaire is 0 to 35. A higher score indicates worse symptomatic. to be assessed at baseline and post-procedure 1 months, 3 months, 6 months and 12 months follow-ups.
Secondary SECODARY EFFICACY ENDPOINT 1 Changes in International Index of Erectile Function (IIEF) questionnaire scores. The questionnaire has 15 questions. Each question is scored from 0-5. A higher score indicates improved erectile function. to be assessed at baseline and post-procedure 1 months, 3 months, 6 months and 12 months follow-ups.
Secondary SECODARY EFFICACY ENDPOINT 2 Changes in size (volume) of the prostate measured by transrectal ultrasound and cystoscope in mL. to be assessed at baseline and post-procedure 1 months, 3 months, 6 months and 12 months follow-ups.
Secondary SECODARY EFFICACY ENDPOINT 3 Change in peak urinary flow (Qmax) in mL/sec. to be assessed at baseline and post-procedure 1 months, 3 months, 6 months and 12 months follow-ups.
Secondary SECODARY EFFICACY ENDPOINT 4 Change in post-void residual urine volume in mL. to be assessed at baseline and post-procedure 1 months, 3 months, 6 months and 12 months follow-ups.
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A